Table 2. Open in new tab Prescribed...

Time period

2006–2007

2008–2009

2010–2011

2012–2013

2014–2015

P-value^a

647

660

604

610

601

Dialysis treatment characteristics

Dialysis vintage (months), mean (SD)

6.9 (3.4)

5.9 (3.4)

6.1 (3.3)

5.9 (3.5)

6.1 (3.5)

0.01

Proportion of APD, %

<0.001

Kt/V/week, mean (SD) (n = 1517)

2.3 (0.6)

2.4 (0.8)

2.3 (0.6)

2.4 (0.6)

2.2 (0.6)

0.08

CCr/week, mean (SD) (n = 1476)

82 (28.0)

79 (27.8)

83 (32.6)

83 (32.8)

81 (27.9)

0.81

Proportion icodextrin, %

<0.001

Proportion APD + icodextrin, %

7.4

8.2

9.3

11.0

12.6

<0.001

Assisted PD, %

1.4

4.2

10.4

10.7

11.8

<0.001

Medications, %

ACEis/ARBs

<0.001

Beta-blockers

0.35

Calcium channel blockers

0.01

Other antihypertensive drugs

<0.001

Diuretics

0.07

Statins

0.67

Erythropoietin/darbepoetin

0.001

Iron (oral/intravenous)

<0.001

Phosphate binders (non-calcium based)

<0.001

Calcium supplements^b

<0.001

Vitamin D3 supplements

0.24

Cinacalcet

0.01

Table 2.

Open in new tab

Prescribed drugs and dialysis treatment characteristics for incident peritoneal patients between 2006 and 2015

Time period	2006–2007	2008–2009	2010–2011	2012–2013	2014–2015	P-value^a
N	647	660	604	610	601
Dialysis treatment characteristics
Dialysis vintage (months), mean (SD)	6.9 (3.4)	5.9 (3.4)	6.1 (3.3)	5.9 (3.5)	6.1 (3.5)	0.01
Proportion of APD, %	15	19	24	23	24	<0.001
Kt/V/week, mean (SD) (n = 1517)	2.3 (0.6)	2.4 (0.8)	2.3 (0.6)	2.4 (0.6)	2.2 (0.6)	0.08
CCr/week, mean (SD) (n = 1476)	82 (28.0)	79 (27.8)	83 (32.6)	83 (32.8)	81 (27.9)	0.81
Proportion icodextrin, %	26	33	31	37	40	<0.001
Proportion APD + icodextrin, %	7.4	8.2	9.3	11.0	12.6	<0.001
Assisted PD, %	1.4	4.2	10.4	10.7	11.8	<0.001
Medications, %
ACEis/ARBs	69	71	69	63	61	<0.001
Beta-blockers	75	73	77	74	77	0.35
Calcium channel blockers	73	76	75	77	83	0.01
Other antihypertensive drugs	23	26	30	31	41	<0.001
Diuretics	89	90	87	88	86	0.07
Statins	59	57	57	61	56	0.67
Erythropoietin/darbepoetin	86	88	82	80	83	0.001
Iron (oral/intravenous)	58	60	57	45	46	<0.001
Phosphate binders (non-calcium based)	57	65	67	71	76	<0.001
Calcium supplements^b	68	68	61	53	52	<0.001
Vitamin D3 supplements	78	83	81	82	81	0.24
Cinacalcet	4	7	7	9	8	0.01

Time period	2006–2007	2008–2009	2010–2011	2012–2013	2014–2015	P-value^a
N	647	660	604	610	601
Dialysis treatment characteristics
Dialysis vintage (months), mean (SD)	6.9 (3.4)	5.9 (3.4)	6.1 (3.3)	5.9 (3.5)	6.1 (3.5)	0.01
Proportion of APD, %	15	19	24	23	24	<0.001
Kt/V/week, mean (SD) (n = 1517)	2.3 (0.6)	2.4 (0.8)	2.3 (0.6)	2.4 (0.6)	2.2 (0.6)	0.08
CCr/week, mean (SD) (n = 1476)	82 (28.0)	79 (27.8)	83 (32.6)	83 (32.8)	81 (27.9)	0.81
Proportion icodextrin, %	26	33	31	37	40	<0.001
Proportion APD + icodextrin, %	7.4	8.2	9.3	11.0	12.6	<0.001
Assisted PD, %	1.4	4.2	10.4	10.7	11.8	<0.001
Medications, %
ACEis/ARBs	69	71	69	63	61	<0.001
Beta-blockers	75	73	77	74	77	0.35
Calcium channel blockers	73	76	75	77	83	0.01
Other antihypertensive drugs	23	26	30	31	41	<0.001
Diuretics	89	90	87	88	86	0.07
Statins	59	57	57	61	56	0.67
Erythropoietin/darbepoetin	86	88	82	80	83	0.001
Iron (oral/intravenous)	58	60	57	45	46	<0.001
Phosphate binders (non-calcium based)	57	65	67	71	76	<0.001
Calcium supplements^b	68	68	61	53	52	<0.001
Vitamin D3 supplements	78	83	81	82	81	0.24
Cinacalcet	4	7	7	9	8	0.01

^aP-values were tested with a Jonckheere–Terpstra trend test for categorical variables and with a linear-by-linear trend test for continuous data. Significant values are in bold.

^bCalcium supplements include calcium-containing phosphate binders.

This Feature Is Available To Subscribers Only